Search
Now showing items 91-100 of 591
Triplet combination of palbociclib, taselisib and fulvestrant and biomarkers for CDK4/6 and PI3-kinase inhibition in breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Targeting the commonly upregulated cell-cycle and PI3-kinase pathway in breast cancer are two of the most novel approaches to tackle the disease, with both strategies having led to clinically meaningful results and licensed ...
Biological effects of combination therapy with oncolytic reovirus and palbociclib
(Institute of Cancer Research (University Of London), 2021-09-30)
Reovirus type 3 Dearing (RtD3) is an oncolytic dsRNA virus with limited single-agent activity in clinical studies but has potential for use in combination regimens. Herein, I sought to discover synergistic drug-virotherapy ...
Reference dosimetry of MRI-guided radiotherapy machines
(Institute of Cancer Research (University Of London), 2021-09-30)
A cutting-edge cancer treatment modality, that integrates MRI guidance and delivery of radiotherapy (MRIgRT), sets a new standard for personalised radiotherapy. There are, however, aspects around the accurate determination ...
Vitamin D deficiency in the pathogenesis of leiomyoma and intravascular leiomyomatosis: A case report and review of the literature.
(2021-02)
This is a case of recurrent intravascular leiomyomatosis in a pre-menopausal woman of African-Caribbean heritage. She presented in 2006 with multiple uterine leiomyomata, tumour invading the inferior vena cava (IVC) extending ...
Rapid uropathogen identification using surface enhanced Raman spectroscopy active filters.
(2021-04-22)
Urinary tract infection is one of the most common bacterial infections leading to increased morbidity, mortality and societal costs. Current diagnostics exacerbate this problem due to an inability to provide timely pathogen ...
BRCA1 loss-of-function triggers metabolic vulnerability to glutamine deprivation
(Institute of Cancer Research (University Of London), 2021-01-31)
Germline and somatic mutations of BRCA1 are associated with cancer initiation and progression. Although the role of BRCA1 is clearly defined in DNA-repair pathways, alternative functions of BRCA1 still remain obscure. Here, ...
Genetic predisposition to prostate cancer: an update.
(SPRINGER, 2021-01-24)
Improvements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate ...
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
(CELL PRESS, 2021-02-04)
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features underpinning CPI sensitization. Here, we ...
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
(ELSEVIER, 2021-01-13)
BACKGROUND: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic ...
Ubiquitylation of MLKL at lysine 219 positively regulates necroptosis-induced tissue injury and pathogen clearance.
(NATURE PORTFOLIO, 2021-06-07)
Necroptosis is a lytic, inflammatory form of cell death that not only contributes to pathogen clearance but can also lead to disease pathogenesis. Necroptosis is triggered by RIPK3-mediated phosphorylation of MLKL, which ...